Clinical Trial Update: Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anti-PD(L)1 therapy combined with SBRT in advanced, platinum-refractory urothelial carcinoma; study is terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• SBRT (stereotactic body radiotherapy)
• anti-PD(L)1 (PD-1/PD-L1 inhibitor)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-12-15